Metabolic signature to predict recurrence after curative resection of hepatocellular carcinoma: a bench-to-bedside study

Tian Yang,Jun Han,Hao Xing,Zhen-Li Li,Han Wu,Li-Yang Sun,Bing Quan,Wen-Tao Yan,Chao Li,Ming-Da Wang
DOI: https://doi.org/10.1016/j.hpb.2019.10.1808
IF: 3.842
2019-01-01
HPB
Abstract:Introduction: Although curative resection is the optimal treatment for hepatocellular carcinoma (HCC), recurrence will develop in more than 60% HCC patients after resection. Thus, it is urgent to identify recurrence-related markers. The study aims to investigate the effectiveness of metabolic alternation in predicting recurrence for patients with HCC. Method: In total, 386 patients with HCC under curative resection in China were sorted and randomly divided in training and validation set. Paired HCC tissues and adjacent non-cancerous tissues were collected and analyzed in metabolomics. Least Absolute Shrinkage and Selection Operation (LASSO) was used to select differential expressed metabolites associated with recurrence and established metabolite expression-based signature. Independent factors for predicting recurrence were identified by univariable and multivariable Cox regression analyses and used for the nomogram construction. Result: After metabolomics analysis, a total of 18 differential expressed metabolites were identified between HCC tissues and adjacent non-cancerous tissues both in training and validation set. Three metabolites of glycerophosphocholine, glycocholic acid and 5-methyltetrahydrofolic acid were highlighted as biomarker candidate associated with HCC recurrence by LASSO regression in the training set. Based on the three metabolites, a metabolic signature was generated to classify patients into high-risk and low-risk groups. The 1-year and 3-year recurrence were 14.7% and 39.2% in low-risk group, and 71.3% and 96.5% in high-risk group, respectively. The prognostic accuracy of this metabolic signature was further confirmed in validation set. Furthermore, a nomogram comprising metabolic signature, cirrhosis, tumor number, tumor diameter, tumor differentiation, and microvascular invasion was generated to predict the 1-year and 3-year recurrence in training set and also performed well in the validation set (concordance index: 0.768 and 0.756). Conclusion: The metabolic signature is a reliable prognostic tool to predict recurrence for HCC patients and offer valuable guidance to plan recurrence surveillance and adjuvant therapy after curative resection.
What problem does this paper attempt to address?